AstraZeneca | AZN

Stock Price
12,090.00
Daily Change
-98.00 -0.80%
Monthly
9.37%
Yearly
-4.43%
Q3 Forecast
11,707.47

Peers Price Chg Day Year Date
AbbVie 212.56 -0.44 -0.21% 9.95% Sep/05
Alcon AG 64.08 0.62 0.98% -19.15% Sep/05
Almirall 10.96 -0.16 -1.44% 27.89% Sep/05
Amgen 283.55 3.45 1.23% -11.52% Sep/05
argenx SE 639.80 8.40 1.33% 31.21% Sep/05
Autolus Therapeutics Ltd 1.46 0.01 0.69% -63.55% Sep/05
AstraZeneca 12,090.00 -98.00 -0.80% -4.43% Sep/05
Bayer 28.16 -0.42 -1.47% -2.61% Sep/05
Biogen 140.67 0.73 0.52% -30.02% Sep/05
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
Fresenius Medical Care 41.99 0.28 0.67% 17.85% Sep/05
Fresenius 46.82 -0.36 -0.76% 40.94% Sep/05
Genmab 1,751.50 6.50 0.37% -5.83% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
Galapagos 28.44 1.84 6.92% 13.85% Sep/05
GRIFOLS 12.30 0.02 0.16% 32.17% Sep/05
GlaxoSmithKline 1,476.00 7.00 0.48% -10.63% Sep/05
Hikma Pharmaceutical 1,720.00 -3.00 -0.17% -12.07% Sep/05
Haleon 365.70 -1.50 -0.41% -6.16% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Lonza 577.40 -0.80 -0.14% 7.68% Sep/05
Merck 109.55 1.05 0.97% -35.10% Sep/05
Merck 84.70 0.65 0.77% -28.15% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Orion 65.90 -1.10 -1.64% 36.67% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Philips 23.80 0.02 0.08% -12.88% Sep/05
Recordati 54.05 -0.25 -0.46% 5.16% Sep/05
Regeneron Pharmaceuticals 573.38 6.16 1.09% -49.30% Sep/05
Roche Holding 274.20 -1.50 -0.54% 0% Sep/05
Sanofi 79.50 0.54 0.68% -23.95% Sep/05
UCB 206.90 2.30 1.12% 28.99% Sep/05

Indexes Price Day Year Date
GB100 9208 -8.67 -0.09% 12.55% Sep/05
EU600 549 -0.88 -0.16% 8.42% Sep/05

AstraZeneca traded at 12,090.00 this Friday September 5th, decreasing 98.00 or 0.80 percent since the previous trading session. Looking back, over the last four weeks, AstraZeneca lost 9.37 percent. Over the last 12 months, its price fell by 4.43 percent. Looking ahead, we forecast AstraZeneca to be priced at 11,707.47 by the end of this quarter and at 11,463.33 in one year, according to Trading Economics global macro models projections and analysts expectations.

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.